These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15059503)

  • 21. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Can osteoporosis be prevented with low doses of estrogen?].
    Trémollières F
    J Gynecol Obstet Biol Reprod (Paris); 1998 Oct; 27(1 Suppl):8-11. PubMed ID: 9864683
    [No Abstract]   [Full Text] [Related]  

  • 24. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Why is the RUTH trial so important?
    Pines A; Levo Y
    Maturitas; 2007 Feb; 56(2):111-2. PubMed ID: 17092665
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A rational approach to evidence gaps in the management of osteoporosis.
    Rosen CJ; Brown SA
    Am J Med; 2005 Nov; 118(11):1183-9. PubMed ID: 16271898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
    Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
    Wien Med Wochenschr Suppl; 2009; (122):1-34. PubMed ID: 19484202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
    Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
    Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to manage osteoporosis after the menopause.
    Compston J
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1007-19. PubMed ID: 16301194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evidence-based approach to hormonal therapies for premenopausal women with fibroids.
    Lethaby AE; Vollenhoven BJ
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):307-31. PubMed ID: 17905660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Raloxifene in postmenopausal women].
    Trémollières F; Ribot C
    Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic prevention of osteoporotic fractures.
    Zizic TM
    Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiresorptive agents, raloxifene, and PHARMAC.
    Gilchrist N
    N Z Med J; 2006 Mar; 119(1230):U1885. PubMed ID: 16532050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The successful development of bisphosphonates in the therapy of osteoporosis].
    Fassbender WJ; Stumpf UC; Kurth A
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?
    Shulman LP
    J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108
    [No Abstract]   [Full Text] [Related]  

  • 40. Drugs for prevention and treatment of postmenopausal osteoporosis.
    Treat Guidel Med Lett; 2005 Oct; 3(38):69-74. PubMed ID: 16177651
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.